Shilin District Court deny OBI’s request to submit the case for trial
Defendant: Reporter Pei amongst the other six reporters Name of the legal agency or court: Taiwan Shilin District Court Reference/case numbers of relevant documents: 2017 Sheng Pan Zi, No. 72 …
OBI Pharma Inc. to attend the investor conference on new drug development, hosted by Masterlink Securities
Date: January 16, 2018 Date of the event: Jan 16, 2018 Time: 14:00:00 (Taiwan Time) Location：Courtyard Marriott Taipei Summary: OBI Pharma Inc. to attend the investor conference on new drug …
Capital increase for new shares to transfer to AP Biosciences, Inc.
Type of merger/acquisition (e.g. merger, consolidation, spin-off,acquisition, or receiving assignment of shares): Receiving assignment of shares Date of occurrence of the event: Dec 29, 2017 Names of companies participating in …
OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.
Taipei, Taiwan, December 22, 2017 6:00pm – OBI Pharma, Inc. (TPEx:4174), a Taiwan biopharma company specializing in the development of novel first-in-class cancer therapeutics that uniquely target Globo Series (including …
OBI Pharma Inc. to attend the 36th J.P. Morgan Annual Healthcare Conference
Date: Jan 9, 2018 Date of the event: Jan 09–Jan 11, 2018 Time: 01:00:00 EST Location: Westin St. Francis Hotel, San Francisco, CA USA Summary: OBI Pharma Inc. to attend …
OBI Pharma Inc. to attend Citi’s 2017 Global Healthcare Conference
Date: Dec 06, 2017 Date of the event: Dec 06–Dec 07, 2017 Time: 21:30:00 EST Location：The Lotte New York Palace, New York USA Summary: OBI Pharma Inc. to attend the …
OBI Pharma Inc. to attend the 2017 Asia Pacific Healthcare Forum, hosted by Goldman Sachs
Date of the event: Nov 29–Nov 30, 2017 Time: 09:00:00 CST Location: Jw Marriott Hotel Hong Kong Level 3 Ballroom Summary: OBI Pharma Inc. to attend the 2017 Asia Pacific …
SFIPC and OBI jointly agreed to withdraw the proceedings on Civil case regarding the dismissal of the Chairman of the company.
Parties to the legal matter: Plaintiff: Securities and Futures Investors Protection Center (SFIPC) Defendant: OBI Pharma, Inc. and Dr. Michael N. Chang (Chairman) Name of the legal agency or court: …
OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Study finds OBI-3424 exerts profound in vivo efficacy and safety against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) expressing AKR1C3. Taipei, Taiwan, October 29, 2017 – OBI …
OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Poster presentation to reveal data regarding in vivo efficacy against patient-derived xenografts (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) Taipei, Taiwan, October 24, 2017 — OBI Pharma, Inc., a …